Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
Summary
In a 51-center Japanese, randomized open-label trial (n=109), afatinib significantly prolonged median progression-free survival versus chemotherapy in treatment-naïve NSCLC with sensitizing uncommon EGFR mutations, prompting early termination and supporting afatinib as standard initial therapy.
Key Findings
- Randomized, open-label trial across 51 institutions enrolled 109 treatment-naïve nonsquamous NSCLC patients with uncommon, sensitizing EGFR mutations.
- Interim analysis triggered early study termination due to efficacy favoring afatinib.
- Afatinib significantly prolonged median PFS versus chemotherapy (reported 10.6 months for afatinib arm in abstract).
Clinical Implications
Afatinib should be considered the first-line option for sensitizing uncommon EGFR-mutant NSCLC; guidelines and reimbursement policies may adapt accordingly.
Why It Matters
First randomized head-to-head data for uncommon EGFR mutations provide high-level evidence to guide first-line therapy beyond common exon 19/L858R mutations.
Limitations
- Open-label design may introduce assessment bias
- Population restricted to Japanese centers; generalizability to other ethnicities requires confirmation
Future Directions
Subgroup analyses by specific uncommon EGFR variants; comparative effectiveness versus third-generation TKIs; global confirmatory trials and QoL outcomes.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized controlled trial providing high-level comparative efficacy
- Study Design
- OTHER